Intrathecal drug delivery systems: an overview of cost-effectiveness evidence
Authors' conclusion
Most analyses suggest that ITDD is cost-effective compared with conventional management strategies, particularly for cancer-related pain and spasticity.
Study context
- Population
- Patients with cancer pain, chronic non-cancer pain, or spasticity
- Comparison
- Intrathecal drug delivery (ITDD) systems vs conventional management strategies
- Outcome
- Cost-effectiveness of ITDD systems
Methodological detailsoverview
- Overview
Main finding
As reported in the abstract
Cost-effectiveness
- Most analyses suggest ITDD is cost-effective vs conventional management, particularly for cancer-related pain and spasticity
- Robustness limited by methodological heterogeneity and reliance on effectiveness data often from small or uncontrolled studies
- Evidence for chronic non-cancer pain especially sparse and inconsistent
- Full and partial economic evaluations, varying perspectives and healthcare settings
Original publication
Intrathecal drug delivery systems: an overview of cost-effectiveness evidence. Reg Anesth Pain Med. Published 8 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →